Natera Inc (NTRA)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer

Signatera™ will be used to evaluate molecular response to APG-157 in the neoadjuvant, induction, and adjuvant settingsNatera, Inc. (NASDAQ: NTRA...

Form 4 - Statement of changes in beneficial ownership of securities

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

Prospera selected as exclusive donor-derived cell-free DNA (dd-cfDNA) monitoring assay for use in Eledon’s planned Phase 3 trial of tegoprubart in...

Form 144 - Report of proposed sale of securities

Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant settingCommercial launch...

Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer

First PMDA-approved molecular residual disease (MRD) test in Japan, supporting the use of Signatera in the adjuvant setting Commercial launch...

NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)Marks third NCCN guideline...

Form 4 - Statement of changes in beneficial ownership of securities